An Open Label, Multicenter Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumors Patients
Solid tumor
Beacon Hospital Sdn Bhd
PRINCIPAL INVESTIGATOR
Dr Tho Lye Mun
Contact: 03-77872830
tholm@beaconhospital.com.my
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Prof Dr Ho Gwo Fuang
CONTACT
SC: Madihah/ Toh Yok Yong
Contact: 03-79492120
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
IBTISAM MUHAMAD NOR
CONTACT
SC: Nurshahida Binti Mohd Nawi
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRAS G12C Mutant Solid Tumors
Solid tumor
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
Fong Yian Ching
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (2023825-12801)
Solid tumor
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Assoc Prof Dr Wan Zamaniah Wan Ishak
CONTACT
SC: Suganiya (03-79492120)
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY PT-01)
For pancreas 1st line and gastric 2-3rd line
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Prof Ho/Prof Wan
CONTACT
SC: Wei Ying
03-79492120